To evaluate the utility of this technology in the context of cancer immunotherapy, we used ImaginAb CD8+ T-cell (89Zr-IAB42M1-14, anti-mouse CD8 minibody) based PET nuclear imaging to selectively monitor CD8+ T-cell migration following treatment of EMT6 (mammary carcinoma) tumor-bearing mice with anti-ICOS agonist mAb as a monotherapy and in combination with PD-1 blocking antibody [6]. This evidence concerns the gene CD8A and neoplasm.